砷剂在血液系统肿瘤中的应用及安全管理  

Clinical Application and Safety Management of Arsenic Trioxide in Hematologic Neoplasms

作　　者：李凌浩[1] 王智[1] 

机构地区：[1]无锡市第二人民医院血液科,江苏无锡214002

出　　处：《医学综述》2013年第23期4277-4280,共4页Medical Recapitulate

摘　　要：三氧化二砷(ATO)能够通过多种途径发挥抗肿瘤效应。自从ATO用于急性早幼粒细胞白血病(APL)的治疗并取得显著疗效以来,其在多发性骨髓瘤、骨髓增生异常综合征、慢性粒细胞白血病的研究性治疗中也获得了良好的效果,提示ATO在血液系统肿瘤中具有潜在的临床应用前景。与此同时,由ATO引发的APL分化综合征、心律失常等不良反应也应引起注意。Arsenic trioxide is able to kill tumor cells through multiple pathways. Since arsenic trioxide was successfully used in treating acute promyelocytic leukemia, it also achieved good effects in treating multi- pie myeloma, myelodysplastic syndrome and chronic myelogenous leukemia, which prompt the potential clini- cal application of arsenic trioxide in hematological neoplasms. But at the same time, the toxic and side effect such as acute promyelocytic leukemia differentiation syndrome and arrhythmia induced by arsenic trioxide should be noticed too.

关 键 词：砷剂 急性早幼粒细胞白血病 多发性骨髓瘤 骨髓增生异常综合征 毒副作用 

分 类 号：R551.3[医药卫生—血液循环系统疾病]